WallStSmart

Adapthealth Corp (AHCO)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 92% more annual revenue ($6.30B vs $3.29B). EW leads profitability with a 17.4% profit margin vs -2.4%. EW earns a higher WallStSmart Score of 61/100 (C+).

AHCO

Hold

45

out of 100

Grade: D+

Growth: 5.3Profit: 3.0Value: 6.7Quality: 3.5
Piotroski: 4/9Altman Z: 0.95

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 6.0Quality: 6.0
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHCOUndervalued (+66.7%)

Margin of Safety

+66.7%

Fair Value

$31.68

Current Price

$10.79

$20.89 discount

UndervaluedFair: $31.68Overvalued
EWUndervalued (+68.2%)

Margin of Safety

+68.2%

Fair Value

$249.70

Current Price

$85.76

$163.94 discount

UndervaluedFair: $249.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHCO1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

EW3 strengths · Avg: 9.3/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

AHCO4 concerns · Avg: 2.8/10
Market CapQuality
$1.49B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.7%3/10

Operating margin of 0.7%

Debt/EquityHealth
1.333/10

Elevated debt levels

Return on EquityProfitability
-5.3%2/10

ROE of -5.3% — below average capital efficiency

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : AHCO

The strongest argument for AHCO centers on Price/Book.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Altman Z-Score, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : AHCO

The primary concerns for AHCO are Market Cap, Operating Margin, Debt/Equity.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.3x leaves little room for execution misses.

Key Dynamics to Monitor

AHCO profiles as a turnaround stock while EW is a growth play — different risk/reward profiles.

AHCO carries more volatility with a beta of 1.45 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

EW generates stronger free cash flow (-21M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 45/100), backed by strong 17.4% margins and 16.7% revenue growth. AHCO offers better value entry with a 66.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adapthealth Corp

HEALTHCARE · MEDICAL DEVICES · USA

AdaptHealth Corp. The company is headquartered in Plymouth Meeting, Pennsylvania.

Visit Website →

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?